Effect of Albumin on Kidney Function After Liver Transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates whether administering human albumin to maintain serum levels above 30g/L for five days can reduce the incidence of acute kidney injury (AKI) in patients who have undergone liver transplantation. Participants will be divided into two groups: one receiving the higher albumin concentration and the other receiving a lower concentration. The primary outcome will be the rate of AKI at Day 7 post-transplantation, comparing the two groups to assess the effectiveness of the treatment. The study aims to provide insights into optimizing post-transplant care for liver transplant recipients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female subjects equal or above 18 yrs old.
* Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
* Capability of understanding the purpose and risks of the study.
* Written informed consent

Exclusion Criteria:

* Fulminant hepatitis
* Kidney injury at baseline (Estimated Glomerular Filtration Rate \< 50 ml/min in Modification of diet in renal disease-6) including hepatorenal syndrome
* Use of an induction agent Basiliximab at liver transplantation
* Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty

Where it's running

• 08_CHRU de Tours Hôpital Trousseau
  Chambray-lès-Tours, France Recruiting
• 03_APHP Hôpital Beaujon
  Clichy, France Recruiting
• 04_CHU de Lille Hôpital Huriez
  Lille, France Recruiting
• 05_HCL Hôpital de la Croix Rousse
  Lyon, France Recruiting
• 06_CHU de Montpellier Hôpital St Eloi
  Montpellier, France Recruiting
• 02_CHU de Bordeaux - Hôpital Haut Leveque
  Pessac, France Recruiting

Study contacts

• Principal investigator: Pauline HOUSSEL-DEBRY, MD — Rennes University Hospital
• Study coordinator: Loïc JACOB
• Email: loic.jacob@chu-rennes.fr
• Phone: +33299282555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

• Everolimus-based calcineurin-free immunosuppression one year after liver transplant

  This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.

  Recruiting Phase 3 Hannover Medical School · Heidelberg, Baden-Wurttemberg and 15 other locations · NCT07739914

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.